What Alea Treats: Main Uses and Benefits

Alea is commonly used to help with the chronic management of Essential Hypertension (High Blood Pressure) in adults. It plays a role in managing the reduction of persistently elevated Systolic and Diastolic Blood Pressure (SBP/DBP) readings, which are key measurable manifestations of the condition. This combination therapy is often employed when a patient's pressure is inadequately controlled by single-agent medication.

The primary therapeutic benefit is focused on long-term Cardiovascular Risk Reduction. By addressing the Elevated Vascular Pressure Load, this medication contributes to easing the chronic strain placed on the heart and blood vessels. This protective effect is relevant for managing the risk of future events, which may include strokes, heart attacks, and the potential progression of organ damage related to chronic hypertension. Its clinical utility includes providing supportive assistance for managing Essential Hypertension and managing the risk of associated cardiovascular events.

---

Quick Fact: Symptomatic Support for Elevated Vascular Pressure

This medication may assist with maintaining functional stability by reducing the pressure load on the heart and blood vessels, which can contribute to easing discomfort during periods of sustained systemic imbalance.

Eligibility Map: Who can and cannot use Alea?

This section outlines the official eligibility and non-eligibility requirements for use of Alea (alectinib), strictly based on governmental regulatory documents from the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).

Official Eligibility Restrictions

Classification	Rule/Population
Contraindicated	Individuals with known hypersensitivity to the active substance alectinib or to any of the product's excipients.
Pregnancy/Lactation	Pregnancy: Use can cause fetal harm; females of reproductive potential must use effective contraception during treatment and for a period after the final dose. Lactation: Use is not recommended; mothers should not breastfeed during treatment and for a specified time after the final dose.
Age-related rules	Safety and effectiveness in pediatric patients (under 18) have not been established by regulatory bodies. The drug is indicated for use in adult patients.
Condition-specific	Patients with pre-existing severe hepatic impairment (Child-Pugh C) require a reduced starting dose for eligibility. Use in patients with unmanageable, severe reactions like Interstitial Lung Disease (ILD)/Pneumonitis or Grade 3-4 liver enzyme elevations requires permanent discontinuation.

Eligibility to use Alea is primarily granted to adult patients whose condition meets the documented therapeutic indications. However, use is prohibited (contraindicated) for those with a known allergy to the drug or its components. Furthermore, the drug is restricted in females of reproductive potential due to the risk of fetal harm, necessitating strict contraceptive measures. Use in patients with severe liver impairment is limited and requires specific dosage modification. The eligibility profile emphasizes the mandatory exclusion of specific populations and conditions where the documented risks outweigh the benefits.

Interactions with other medicines and products

The official regulatory profile for Alea (Amlodipine/Olmesartan Medoxomil) documents several interaction patterns based on the combination's two active components.

---

Interaction Classifications and Restrictions

The drug is contraindicated for co-administration with Aliskiren in patients with diabetes or moderate-to-severe renal impairment.

• Pharmacodynamic Reinforcement: Co-administration with Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) may result in a documented loss of antihypertensive effect and an increased risk of renal impairment. Dual blockade of the Renin-Angiotensin System (RAAS) with other agents also increases the risk of hyperkalemia, hypotension, and renal changes. Co-administration with Lithium may increase serum lithium concentrations and toxicity.
• Exposure-Modifying Interactions: The amlodipine component's metabolism is sensitive to enzyme modulators. Potent CYP3A inhibitors cause increased systemic exposure to Amlodipine, while CYP3A inducers may decrease concentrations. Amlodipine also increases the systemic exposure of Simvastatin, necessitating a regulatory dose constraint of 20 mg daily, and similarly affects Cyclosporin and Tacrolimus.
• Timing and Supplements: Co-administration with Colesevelam Hydrochloride reduces Olmesartan exposure; therefore, Olmesartan must be administered at least 4 hours prior to the Colesevelam dose. Co-use with Potassium-containing agents may result in increased serum potassium levels.
• Population Notes: Decreased clearance of Amlodipine, resulting in increased systemic exposure, is documented in elderly patients (75 years and older) and those with hepatic impairment.

---

The regulatory documents define the product's interaction structure primarily around pharmacokinetic modification and pharmacodynamic reinforcement concerning the RAAS.

How Alea Works

Alea is a therapeutic protein that functions as a high-affinity decoy receptor. Its mechanism involves extracellular sequestration of specific signaling molecules, notably Vascular Endothelial Growth Factor A (VEGF-A), VEGF-B, and Placental Growth Factor (PlGF). The binding interaction neutralizes these growth factors, preventing them from activating their cognate cell surface receptors (VEGFR-1 and VEGFR-2) on endothelial cells.

This blockade disrupts the signaling cascade that promotes cell proliferation and migration, thereby modulating the Angiogenesis pathway. The central consequence is the suppression of new, often structurally compromised, blood vessel formation (pathological angiogenesis). Furthermore, this mechanism influences vascular permeability, reducing the signal that compromises the integrity of blood vessel walls. This system-level modulation results in an alteration of localized fluid dynamics and a reduction of plasma components escaping into surrounding tissues.

Standard Usage Principles for Alea (Amlodipine/Olmesartan Medoxomil)

Alea is an orally administered fixed-dose combination formulated as a film-coated tablet, establishing the single route of administration. The product is intended for long-term chronic therapy to manage hypertension, and its use is governed by established dosing and administration rules.

The core administration pattern requires the tablet to be taken once daily (QD). To simplify adherence, the medication is typically taken with or without food. The entire daily dose should be swallowed whole as a single administration.

---

Standardized Dosing Constraints

The typical adult starting dose is 5 mg Amlodipine / 20 mg Olmesartan Medoxomil. The maximum daily dosage is set at 10 mg/40 mg. Regarding schedule disruptions, standard protocol involves continuing with the next scheduled dose and not taking two doses at once if a dose is missed.

---

Population-Specific Use

Clinical considerations indicate that patients with severe renal or hepatic impairment require careful dose consideration, often necessitating a lower initial dose of the individual components. Additionally, careful selection of the initial dosage is utilized for older adults (aged 65 years and over).

Research Evidence for Alea (Amlodipine/Olmesartan)

---

Evidence for Use in Managing Essential Hypertension

Research has focused on understanding the effects of this fixed-dose combination pill for adults with Essential Hypertension (high blood pressure). The main body of evidence comes from Randomized Controlled Trials (RCTs), which were applied in studies examining measured physiological signs (blood pressure). These trials typically compare the fixed combination to an inactive pill (placebo) and to taking just one of the active ingredients alone (monotherapy). The studies also included open-label follow-up phases that monitored patients over a longer duration.

The most robust data describing the combination's effect on blood pressure was studied for short follow-up periods, often around two to three months. These follow-up durations were limited, focusing on the immediate effects on blood pressure readings (a surrogate marker). Because of this, comparative evidence is limited regarding the combination against other dual therapies, and long-term effects beyond a year are not fully established by these initial regulatory trials.

---

Long-Term Research and Cardiovascular Risk

Research was evaluated in the context of the goal of achieving long-term Cardiovascular Risk Reduction. The evidence for this long-term perspective largely relies on data gathered about the component drug classes—Calcium Channel Blockers (CCBs) and Angiotensin II Receptor Blockers (ARBs)—rather than a single, multi-year trial focused only on this specific fixed combination.

The broader scientific evidence for these established classes contributes to understanding symptom patterns related to the fact that consistent and sustained blood pressure control data show patterns related to a reduced risk of serious cardiovascular events. The combination was observed in studies exploring target blood pressure levels, which may impact outcomes monitoring physiological strain or stress on the heart and blood vessels.

However, a key limitation is that no dedicated, multi-year Randomized Controlled Trial (RCT) on the Alea combination itself has been conducted that was specifically designed to compare its performance in reducing the actual rates of heart attacks and strokes against a control group over several years. Therefore, the long-term perspective is inferred based on the established principles of effective blood pressure management and the component classes.

Key Studies & References

1. Combination Therapy with Olmesartan and Amlodipine in the Treatment of Hypertension (Review of combination therapy and guidelines)

Common questions about Alea (FAQ)

---

Q: What is the difference between Alea and other similar medicines?

A: Official product information identifies Alea as a fixed-dose combination medicine. This means it combines two different types of blood pressure medication—a Calcium Channel Blocker (Amlodipine) and an Angiotensin II Receptor Blocker (Olmesartan Medoxomil)—into a single tablet. This combination targets high blood pressure using two established mechanisms simultaneously.

---

Q: How long does it take for Alea to start working?

A: Regulatory documents indicate that the maximum blood pressure-lowering effect of the fixed combination is generally reached within two weeks after a dose adjustment.

---

Q: Is Alea safe to take long-term?

A: Alea is officially indicated for the management of chronic high blood pressure. While the initial regulatory trials for the specific combination were often limited to short-term follow-up, the established benefits of sustained blood pressure control are based on the long-standing evidence for the component drug classes (CCBs and ARBs) it contains.

---

Q: What is the long-term safety profile of Alea?

A: The long-term safety is based on adverse events observed in clinical studies and post-marketing reports. The long-term evidence is derived from studies on the component drug classes, which support the established benefit of consistent blood pressure management. This perspective guides the use of Alea for chronic blood pressure management.

---

Q: Are there special restrictions for older adults taking Alea?

A: Yes, official guidelines advise caution and careful selection of the initial dosage for older adults (aged 65 years and over). Furthermore, regulatory documents note that decreased clearance of the Amlodipine component, which can lead to increased exposure in the body, is documented in elderly patients who are 75 years and older.

---

Q: Does Alea cause weight gain or loss?

A: The official safety documents list peripheral oedema (swelling or fluid retention) as a common side effect, which may affect up to 1 in 10 people. However, regulatory labels do not explicitly note significant weight gain or weight loss as common or serious adverse reactions.

---

Q: Is it normal to feel tired after starting Alea?

A: Yes, regulatory safety documents confirm that fatigue is listed as a common side effect. This means it has been reported to affect up to 1 in 10 people taking the medication.

---

Q: Are the side effects of Alea permanent?

A: The official safety documents describe serious but non-permanent adverse reactions, such as acute reversible renal failure, which is temporary. Common side effects like headache and dizziness are typically not described as permanent effects in regulatory information.

---

Q: Can Alea be crushed or split?

A: According to the official product information, the Alea film-coated tablet should be swallowed whole as a single administration to ensure it is used as intended.

---

Q: Is Alea considered a controlled substance?

A: No. Alea (Amlodipine/Olmesartan Medoxomil) is a synthetic, prescription-only drug that is classified as a Combination Antihypertensive and is not listed under the U.S. Controlled Substances Act.

---

Q: Does Alea have a generic version available yet?

A: Yes, regulatory listings from the National Institutes of Health (DailyMed) confirm that the combination of Amlodipine and Olmesartan Medoxomil tablets is available from multiple manufacturers, indicating the availability of a generic version.

---

Q: Are there any foods or drinks I should avoid while on Alea?

A: Official warnings note a moderate interaction between the components (Amlodipine and Olmesartan) and alcohol (ethanol) due to additive effects that lower blood pressure. Co-use with potassium-containing agents is noted in regulatory information for its potential to lead to increased serum potassium levels.

---

Q: How long does Alea stay in your system?

A: Official pharmacokinetic data indicates that the component Olmesartan has an elimination half-life of approximately 13 hours. The half-life of Amlodipine, the other component, is documented to be between 30 and 50 hours.

---

Q: Can I take Alea if I have a history of heart issues?

A: Official warnings note that special caution is advised for patients with certain heart conditions, such as severe congestive heart failure, specific types of valve stenosis, or obstructive hypertrophic cardiomyopathy.

---

Q: Where does the official information about Alea come from?

A: The official information, including the approved uses, safety profile, and warnings, is sourced directly from governmental regulatory bodies. These include the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), which publish and maintain the authoritative product labeling.

---

Q: Is Alea a high-risk medication?

A: Official documents define specific safety constraints, including the potential for fetal harm (a contraindication in later pregnancy), severe allergic reactions like angioedema, and risks associated with low blood pressure. These requirements are set by regulatory bodies for all prescription drugs.

---

Q: Is Alea chemically similar to any common illegal substances?

A: Alea is a combination of two synthetic, pharmaceutical agents, Amlodipine and Olmesartan Medoxomil. It is officially classified as a Combination Antihypertensive and is not a controlled substance.

---

Q: Has Alea received approval in different countries?

A: Yes, regulatory citations confirm that the fixed-dose combination has received approval from authorities in different international regions. Official sources include the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

How to Store and Dispose of Alea

This section outlines the official, regulatory storage and disposal requirements for Alea, as documented in government-approved labeling.

Storage Requirements

Feature	Official Regulatory Statement
Temperature Range	Store at controlled room temperature, typically 20 C to 25 C.
Protection	Keep in the original container to protect from light and moisture.
Prohibited Conditions	Do not freeze or expose the product to excessive heat.
Child Safety	Must be stored out of the sight and reach of children.

Handling and Disposal

To maintain the quality of the product, keep the container tightly closed and do not remove the medicine from its blister packaging until ready to use. If Alea requires reconstitution, follow the labeled instructions for the specific 'in-use' time limit before discarding. Unused or expired Alea must be disposed of according to official guidelines, typically through a drug take-back program, and should not be placed in household trash or flushed down the sink or toilet.